Regulatory approval

Published by the European Medicines Agency.

The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) either following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.

This is written in the approval document as:

ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): (i) following ASCT, or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.

Citation

Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin